The technique aims to overcome major manufacturing bottlenecks in T cell receptor (TCR) therapy by generating off-the-shelf treatments for solid tumors without triggering graft-versus-host disease.
How Scalable TCR Therapy Works
T cell receptor therapy genetically reprograms immune cells to hunt down cancer. Unlike CAR T-cell therapy, which can only spot proteins naturally appearing outside a cell, TCR therapy catches small protein fragments from inside the cell that get carried to the surface like name tags, according to research from UCLA. This capability provides access to a much wider range of cancer targets, which is critical for solid tumors where most cancer-driving markers remain hidden inside the cell.
Currently available approaches require each dose to be custom-made from a patient’s own T cells, a process taking weeks and costing well into the six figures. While researchers have explored engineering donor-derived T cells for off-the-shelf use, that method carries the risk of graft-versus-host disease, where transplanted immune cells attack healthy tissues. As co-senior author Lili Yang, professor of microbiology, immunology and molecular genetics and member of the UCLA Broad Stem Cell Research Center and UCLA Health Jonsson Comprehensive Cancer Center, noted, the UCLA group avoided these two obstacles by beginning with umbilical cord blood stem cells, which naturally produce every variety of blood and immune cell.
Engineering Stem Cells Before Maturation
The research team added a gene for a receptor targeting NY-ESO-1, a protein found in many solid tumors, before growing the engineered stem cells into T cells in the lab. Introducing the receptor early prevents the stem cells from developing their own natural receptors during maturation.
“Stem cells are undifferentiated—they’re not yet mature T cells with a fixed receptor already in place,” expressed Yichen (John) Zhu, co-first author and graduate student in the UCLA Broad Stem Cell Research Center Training Program. “When we differentiate our engineered stem cells into T cells, essentially all of the resulting cells carry the same receptor and go after the same tumor target.”
This approach eliminates the need to silence random natural receptors with extra gene editing, a step required when starting from mature donor T cells that could otherwise attack a patient’s healthy tissue.
Guarding Against Antigen Escape
Solid tumors often shed or hide the markers a therapy is built to find, a phenomenon known as antigen escape. To prevent this, the engineered cells—named AlloESO-T cells—also carry natural killer cell receptors. This separate detection system identifies stress signals displayed on the surface of many tumor cells, giving the therapy a backup mechanism to recognize and destroy cancer cells even if the NY-ESO-1 target is absent.
In mouse models of ovarian cancer and melanoma, a single dose of AlloESO-T cells kept tumors in check and extended survival without triggering dangerous side effects. The platform advances efforts toward standardized, pre-manufactured cancer therapies that can be frozen and deployed immediately when a patient requires treatment.